 Liping Yu
Concepts (223)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Autoantibodies | 50 | 2023 | 1354 | 5.890 |
Why?
| | Diabetes Mellitus, Type 1 | 54 | 2023 | 3248 | 3.840 |
Why?
| | Luminescent Measurements | 7 | 2021 | 74 | 3.140 |
Why?
| | Celiac Disease | 7 | 2023 | 264 | 2.350 |
Why?
| | Islets of Langerhans | 22 | 2023 | 728 | 2.230 |
Why?
| | Glutamate Decarboxylase | 15 | 2022 | 160 | 2.050 |
Why?
| | Electrochemical Techniques | 3 | 2020 | 45 | 1.820 |
Why?
| | High-Throughput Screening Assays | 3 | 2020 | 123 | 1.740 |
Why?
| | Autoimmune Diseases | 5 | 2020 | 392 | 1.530 |
Why?
| | Zinc Transporter 8 | 10 | 2021 | 86 | 1.470 |
Why?
| | Mass Screening | 9 | 2021 | 1011 | 1.350 |
Why?
| | Insulin Antibodies | 10 | 2016 | 102 | 1.270 |
Why?
| | Prediabetic State | 6 | 2015 | 220 | 1.230 |
Why?
| | Transglutaminases | 5 | 2023 | 142 | 1.190 |
Why?
| | Cation Transport Proteins | 8 | 2013 | 123 | 1.180 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 6 | 2016 | 58 | 1.040 |
Why?
| | Sensitivity and Specificity | 14 | 2022 | 1700 | 0.980 |
Why?
| | Proinsulin | 4 | 2016 | 49 | 0.960 |
Why?
| | Insulin | 18 | 2021 | 2079 | 0.960 |
Why?
| | Diagnostic Techniques, Endocrine | 3 | 2019 | 14 | 0.730 |
Why?
| | Autoantigens | 7 | 2021 | 397 | 0.700 |
Why?
| | Autoimmunity | 12 | 2023 | 818 | 0.580 |
Why?
| | Biomarkers | 6 | 2022 | 3418 | 0.490 |
Why?
| | Child, Preschool | 22 | 2023 | 9083 | 0.450 |
Why?
| | Glucose Intolerance | 1 | 2015 | 138 | 0.440 |
Why?
| | Child | 28 | 2023 | 18362 | 0.430 |
Why?
| | Humans | 57 | 2023 | 114925 | 0.400 |
Why?
| | Luminescence | 4 | 2016 | 33 | 0.400 |
Why?
| | Infant | 17 | 2023 | 7936 | 0.380 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 82 | 0.370 |
Why?
| | Adolescent | 24 | 2023 | 17826 | 0.370 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2022 | 2096 | 0.350 |
Why?
| | Quality Improvement | 1 | 2017 | 954 | 0.340 |
Why?
| | Immunologic Factors | 1 | 2011 | 221 | 0.330 |
Why?
| | Radioimmunoassay | 4 | 2016 | 164 | 0.310 |
Why?
| | Male | 25 | 2021 | 55655 | 0.310 |
Why?
| | Protein Precursors | 2 | 2021 | 119 | 0.310 |
Why?
| | Radioligand Assay | 2 | 2009 | 43 | 0.310 |
Why?
| | Female | 28 | 2021 | 59571 | 0.300 |
Why?
| | Peptide Fragments | 7 | 2016 | 668 | 0.300 |
Why?
| | Risk Factors | 10 | 2021 | 8637 | 0.280 |
Why?
| | Antibodies, Antinuclear | 1 | 2007 | 60 | 0.280 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2007 | 42 | 0.280 |
Why?
| | Young Adult | 11 | 2021 | 10476 | 0.270 |
Why?
| | Adult | 15 | 2021 | 30604 | 0.260 |
Why?
| | Disease Progression | 8 | 2017 | 2392 | 0.250 |
Why?
| | Addison Disease | 3 | 2012 | 40 | 0.240 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2007 | 221 | 0.240 |
Why?
| | CD4-Positive T-Lymphocytes | 4 | 2021 | 966 | 0.230 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 5 | 2011 | 797 | 0.220 |
Why?
| | Middle Aged | 10 | 2021 | 26801 | 0.200 |
Why?
| | Isoenzymes | 2 | 2004 | 285 | 0.200 |
Why?
| | Electrochemistry | 1 | 2021 | 79 | 0.190 |
Why?
| | Predictive Value of Tests | 6 | 2015 | 1801 | 0.190 |
Why?
| | China | 1 | 2021 | 162 | 0.190 |
Why?
| | Genotype | 9 | 2016 | 1775 | 0.190 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 254 | 0.190 |
Why?
| | Follow-Up Studies | 6 | 2021 | 4427 | 0.180 |
Why?
| | Polymorphism, Genetic | 4 | 2017 | 612 | 0.180 |
Why?
| | DNA | 1 | 2007 | 1351 | 0.180 |
Why?
| | Steroid 21-Hydroxylase | 3 | 2012 | 30 | 0.170 |
Why?
| | Health Fairs | 1 | 2019 | 9 | 0.170 |
Why?
| | Risk Assessment | 3 | 2020 | 2975 | 0.170 |
Why?
| | Prognosis | 5 | 2021 | 3344 | 0.170 |
Why?
| | Disease Susceptibility | 1 | 2020 | 316 | 0.160 |
Why?
| | Cohort Studies | 3 | 2021 | 4903 | 0.160 |
Why?
| | Epitopes | 4 | 2021 | 436 | 0.150 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2023 | 620 | 0.150 |
Why?
| | Population Surveillance | 1 | 2020 | 392 | 0.150 |
Why?
| | Polyendocrinopathies, Autoimmune | 1 | 2017 | 18 | 0.150 |
Why?
| | Antibody Specificity | 4 | 2011 | 176 | 0.150 |
Why?
| | Disease Management | 1 | 2020 | 563 | 0.140 |
Why?
| | T-Lymphocytes | 5 | 2023 | 1749 | 0.140 |
Why?
| | Insulin-Secreting Cells | 2 | 2017 | 317 | 0.140 |
Why?
| | HLA-DQ Antigens | 5 | 2016 | 176 | 0.130 |
Why?
| | Mice, Inbred NOD | 7 | 2008 | 561 | 0.130 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 525 | 0.130 |
Why?
| | Incidence | 1 | 2021 | 2316 | 0.130 |
Why?
| | Transcription Factors | 2 | 2017 | 1530 | 0.120 |
Why?
| | Protein Tyrosine Phosphatases | 3 | 2004 | 147 | 0.110 |
Why?
| | Case-Control Studies | 2 | 2011 | 3008 | 0.110 |
Why?
| | Poly I-C | 2 | 2004 | 51 | 0.110 |
Why?
| | Reproducibility of Results | 2 | 2019 | 2769 | 0.110 |
Why?
| | Biopsy | 1 | 2016 | 1045 | 0.110 |
Why?
| | Histocompatibility Antigens Class I | 3 | 2009 | 174 | 0.100 |
Why?
| | HLA-DR Antigens | 4 | 2016 | 220 | 0.100 |
Why?
| | Iodine Radioisotopes | 1 | 2011 | 126 | 0.090 |
Why?
| | Pedigree | 3 | 2017 | 467 | 0.090 |
Why?
| | Glucose Tolerance Test | 1 | 2012 | 343 | 0.090 |
Why?
| | Risk | 1 | 2013 | 815 | 0.090 |
Why?
| | Rituximab | 1 | 2011 | 151 | 0.090 |
Why?
| | HLA-DR4 Antigen | 3 | 2011 | 76 | 0.090 |
Why?
| | Prospective Studies | 5 | 2016 | 6218 | 0.090 |
Why?
| | HLA-DR3 Antigen | 3 | 2011 | 79 | 0.090 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 718 | 0.080 |
Why?
| | Aged | 4 | 2021 | 19120 | 0.080 |
Why?
| | Mice | 13 | 2008 | 14935 | 0.080 |
Why?
| | Family | 1 | 2012 | 590 | 0.080 |
Why?
| | Laboratories | 1 | 2009 | 95 | 0.080 |
Why?
| | Peptides | 2 | 2023 | 848 | 0.070 |
Why?
| | Diagnosis, Differential | 1 | 2011 | 1355 | 0.070 |
Why?
| | Radioimmunoprecipitation Assay | 1 | 2007 | 6 | 0.070 |
Why?
| | Interferon-alpha | 2 | 2009 | 187 | 0.070 |
Why?
| | Antibody Formation | 1 | 2008 | 267 | 0.070 |
Why?
| | Histocompatibility Antigens | 1 | 2008 | 100 | 0.070 |
Why?
| | Seroepidemiologic Studies | 2 | 2023 | 138 | 0.070 |
Why?
| | Double-Blind Method | 1 | 2011 | 1663 | 0.070 |
Why?
| | Recombinant Fusion Proteins | 1 | 2009 | 617 | 0.070 |
Why?
| | Membrane Proteins | 2 | 2004 | 1022 | 0.070 |
Why?
| | CD4 Antigens | 2 | 2003 | 124 | 0.070 |
Why?
| | Animals | 14 | 2008 | 31837 | 0.070 |
Why?
| | C-Peptide | 2 | 2016 | 138 | 0.060 |
Why?
| | Models, Biological | 1 | 2011 | 1630 | 0.060 |
Why?
| | Antibodies, Heterophile | 1 | 2004 | 13 | 0.060 |
Why?
| | Twins, Dizygotic | 1 | 2004 | 182 | 0.060 |
Why?
| | Immunity, Mucosal | 1 | 2004 | 84 | 0.060 |
Why?
| | Endocrine System Diseases | 1 | 2004 | 30 | 0.060 |
Why?
| | Glycolipids | 1 | 2004 | 35 | 0.060 |
Why?
| | Siblings | 1 | 2004 | 223 | 0.060 |
Why?
| | Remission Induction | 1 | 2004 | 233 | 0.050 |
Why?
| | Genetic Testing | 1 | 2005 | 379 | 0.050 |
Why?
| | Longitudinal Studies | 2 | 2021 | 2382 | 0.050 |
Why?
| | Osteopontin | 1 | 2022 | 32 | 0.050 |
Why?
| | Fetal Blood | 1 | 2004 | 270 | 0.050 |
Why?
| | Colorado | 2 | 2023 | 4089 | 0.050 |
Why?
| | Epitopes, B-Lymphocyte | 1 | 2021 | 16 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2002 | 250 | 0.050 |
Why?
| | Seroconversion | 1 | 2021 | 45 | 0.050 |
Why?
| | Canada | 1 | 2002 | 322 | 0.050 |
Why?
| | Mice, Inbred BALB C | 4 | 2004 | 1152 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2008 | 1893 | 0.050 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2002 | 162 | 0.050 |
Why?
| | Infant, Newborn | 4 | 2005 | 5035 | 0.050 |
Why?
| | Prevalence | 2 | 2023 | 2251 | 0.040 |
Why?
| | Age Factors | 2 | 2004 | 2891 | 0.040 |
Why?
| | Blood Specimen Collection | 1 | 2019 | 32 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2023 | 522 | 0.040 |
Why?
| | Tissue Donors | 1 | 2021 | 317 | 0.040 |
Why?
| | Proportional Hazards Models | 2 | 2016 | 1080 | 0.040 |
Why?
| | Adrenocorticotropic Hormone | 2 | 2012 | 129 | 0.040 |
Why?
| | Alleles | 3 | 2009 | 791 | 0.040 |
Why?
| | Age of Onset | 2 | 2011 | 448 | 0.040 |
Why?
| | Loss of Function Mutation | 1 | 2017 | 36 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2023 | 4406 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2002 | 934 | 0.040 |
Why?
| | Community Health Services | 1 | 2019 | 212 | 0.040 |
Why?
| | Phenotype | 2 | 2021 | 2817 | 0.040 |
Why?
| | Antibodies, Monoclonal | 1 | 2003 | 1270 | 0.040 |
Why?
| | Hydrocortisone | 2 | 2012 | 270 | 0.040 |
Why?
| | Mice, Transgenic | 3 | 2008 | 1953 | 0.030 |
Why?
| | Time Factors | 3 | 2016 | 6125 | 0.030 |
Why?
| | Protein Domains | 1 | 2017 | 207 | 0.030 |
Why?
| | Proteomics | 1 | 2022 | 844 | 0.030 |
Why?
| | Blood Glucose | 3 | 2016 | 1821 | 0.030 |
Why?
| | HLA-DQ beta-Chains | 2 | 2009 | 58 | 0.030 |
Why?
| | Antibody Affinity | 1 | 2016 | 52 | 0.030 |
Why?
| | Polymerase Chain Reaction | 2 | 2009 | 995 | 0.030 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2008 | 744 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2022 | 1197 | 0.030 |
Why?
| | Organ Specificity | 2 | 2007 | 270 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 591 | 0.030 |
Why?
| | Injections, Subcutaneous | 2 | 2004 | 134 | 0.030 |
Why?
| | Adoptive Transfer | 2 | 2005 | 198 | 0.030 |
Why?
| | Mice, SCID | 2 | 2005 | 320 | 0.030 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 2 | 2004 | 44 | 0.030 |
Why?
| | Spleen | 2 | 2005 | 485 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2015 | 737 | 0.030 |
Why?
| | Administration, Oral | 2 | 2004 | 731 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1440 | 0.030 |
Why?
| | Renin | 1 | 2012 | 31 | 0.030 |
Why?
| | Enzyme-Linked Immunospot Assay | 1 | 2011 | 34 | 0.020 |
Why?
| | Graves Disease | 1 | 2009 | 32 | 0.020 |
Why?
| | HLA-DRB1 Chains | 1 | 2009 | 98 | 0.020 |
Why?
| | Microsatellite Repeats | 1 | 2009 | 136 | 0.020 |
Why?
| | Homozygote | 1 | 2009 | 188 | 0.020 |
Why?
| | Mice, Knockout | 2 | 2005 | 2586 | 0.020 |
Why?
| | International Cooperation | 1 | 2009 | 172 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2011 | 723 | 0.020 |
Why?
| | Pediatrics | 1 | 2015 | 984 | 0.020 |
Why?
| | ROC Curve | 1 | 2009 | 448 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2008 | 168 | 0.020 |
Why?
| | Age Distribution | 1 | 2007 | 340 | 0.020 |
Why?
| | United States | 1 | 2002 | 12209 | 0.020 |
Why?
| | Rats | 2 | 2004 | 4963 | 0.020 |
Why?
| | Thyroglobulin | 1 | 2005 | 17 | 0.020 |
Why?
| | Iodide Peroxidase | 1 | 2005 | 27 | 0.020 |
Why?
| | Integrin alpha Chains | 1 | 2004 | 22 | 0.020 |
Why?
| | Disease Models, Animal | 2 | 2004 | 3549 | 0.020 |
Why?
| | Family Health | 1 | 2005 | 194 | 0.010 |
Why?
| | Histocompatibility Testing | 1 | 2004 | 118 | 0.010 |
Why?
| | B7-1 Antigen | 1 | 2004 | 54 | 0.010 |
Why?
| | False Positive Reactions | 1 | 2004 | 109 | 0.010 |
Why?
| | Endocrine System | 1 | 2004 | 19 | 0.010 |
Why?
| | Mice, Inbred C57BL | 2 | 2004 | 4718 | 0.010 |
Why?
| | Single-Blind Method | 1 | 2004 | 258 | 0.010 |
Why?
| | HLA Antigens | 1 | 2005 | 224 | 0.010 |
Why?
| | Cyclophosphamide | 1 | 2003 | 217 | 0.010 |
Why?
| | T-Box Domain Proteins | 1 | 2003 | 92 | 0.010 |
Why?
| | Delivery, Obstetric | 1 | 2004 | 119 | 0.010 |
Why?
| | Species Specificity | 1 | 2004 | 547 | 0.010 |
Why?
| | Reference Values | 1 | 2004 | 741 | 0.010 |
Why?
| | Antigens, CD | 1 | 2004 | 443 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2008 | 1523 | 0.010 |
Why?
| | CD8 Antigens | 1 | 2002 | 69 | 0.010 |
Why?
| | HLA-A Antigens | 1 | 2002 | 50 | 0.010 |
Why?
| | Chronic Disease | 1 | 2008 | 1593 | 0.010 |
Why?
| | Glucagon | 1 | 2002 | 93 | 0.010 |
Why?
| | Models, Immunological | 1 | 2002 | 92 | 0.010 |
Why?
| | Antibodies | 1 | 2003 | 372 | 0.010 |
Why?
| | Major Histocompatibility Complex | 1 | 2002 | 219 | 0.010 |
Why?
| | Regression Analysis | 1 | 2004 | 947 | 0.010 |
Why?
| | Immunization | 1 | 2004 | 402 | 0.010 |
Why?
| | Anaphylaxis | 1 | 2004 | 148 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2008 | 3897 | 0.010 |
Why?
| | Survival Analysis | 1 | 2003 | 1220 | 0.010 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2002 | 353 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2004 | 1988 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2008 | 2102 | 0.010 |
Why?
| | Proteins | 1 | 2004 | 912 | 0.010 |
Why?
| | Immunity, Innate | 1 | 2004 | 724 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2002 | 1635 | 0.010 |
Why?
| | Vaccination | 1 | 2003 | 1205 | 0.010 |
Why?
| | Pregnancy | 1 | 2004 | 5525 | 0.010 |
Why?
|
|
Yu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|